What is the long-term trend for Integra LifeSciences's contingent consideration fair value adjustments?

Over 4 years (2021 to 2025), Integra LifeSciences's contingent consideration fair value adjustments has grown at a 77.2% compound annual growth rate (CAGR), from -$2.16M to -$21.33M.

Integra LifeSciences IART Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Boston ScientificBSX

-$30M-700%

Globus MedicalGMED

——

AbbVieABBV

——

Merit Medical SystemsMMSI

——

CONMEDCNMD

——

ArtivionAORT

——

Other financials

Income statement

See full

Revenue$391.9M+2.4%

Gross profit$217.0M+11.6%

Operating income$11.5M+174%

Net income-$4.6M+81.7%

EPS (diluted)-$0.06+81.8%

Balance sheet

See full

Cash & equivalents$236.8M-1.0%

Total debt$2.0B+3.2%

Total equity$1.0B-31.6%

Total assets$3.6B-11.7%

Cash flow

See full

Operating cash flow$9.8M+187%

CapEx$14.8M-48.7%

Free cash flow-$5.0M+87.4%

Valuation

See full

Market cap$1.38B+53.4%

Enterprise value$3.12B+21.1%

P/S0.8×+0.3×

Profitability

See full

Gross margin51.9%-1.6pp

Operating margin-29.8%-30.3pp

Net margin-30.1%—

FCF margin3.8%-6.3pp

Returns & leverage

See full

Return on equity-38.6%—

Debt / equity1.9×+0.6×

Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Integra LifeSciences's contingent consideration fair value adjustments?: Integra LifeSciences (IART) reported contingent consideration fair value adjustments of -$1.29M in Q1 2026.
How has Integra LifeSciences's contingent consideration fair value adjustments changed year-over-year?: Integra LifeSciences's contingent consideration fair value adjustments decreased by 698.1% year-over-year, from -$162K to -$1.29M.
What is the long-term trend for Integra LifeSciences's contingent consideration fair value adjustments?: Over 4 years (2021 to 2025), Integra LifeSciences's contingent consideration fair value adjustments has grown at a 77.2% compound annual growth rate (CAGR), from -$2.16M to -$21.33M.